InterCure Regains Nasdaq Minimum Bid Compliance
Analysis based on 6 articles · First reported Sep 08, 2026 · Last updated Sep 09, 2026
The confirmation removes the immediate threat of delisting, which could have severely impacted InterCure's liquidity and access to capital. The stock closed at $5.39 on September 8, 2026, well above the $1.00 minimum, indicating investor confidence in the company's continued listing.
InterCure Ltd., an Israeli cannabis company trading on Nasdaq under the ticker INCR, received confirmation on September 8, 2026, from Nasdaq that it had regained compliance with the minimum bid price requirement (Nasdaq Listing Rule 5450(a)(1)). This followed a period of non-compliance that began when Nasdaq notified the company on February 25, 2026, that its share price had closed below $1.00 for 30 consecutive business days. InterCure was granted a 180-day compliance period expiring August 24, 2026. After failing to regain compliance by that deadline, Nasdaq issued a delisting notice on September 1, 2026. However, the company's shares subsequently traded at or above $1.00 for ten consecutive business days from August 24 through September 4, 2026, leading Nasdaq to confirm compliance and close the matter. This allows InterCure to continue trading on The Nasdaq Global Market, preserving its access to U.S. capital markets and investor visibility.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard